Welcome to our dedicated page for DENALI CAPITAL ACQ CP A SEC filings (Ticker: DNQAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for DENALI CAPITAL ACQ CP A (DNQAF) provides access to regulatory documents that trace the evolution of Denali Capital Acquisition Corp. into Semnur Pharmaceuticals, Inc. These filings explain how DNQAF relates to the company’s current trading symbols and capital structure.
A Form 8-K dated September 26, 2025 describes the domestication of Denali from the Cayman Islands to Delaware and the completion of a Business Combination in which Denali Merger Sub Inc. merged with and into Semnur Pharmaceuticals, Inc. (Legacy Semnur). Legacy Semnur became a wholly owned subsidiary of the domesticated entity, and Denali changed its name to Semnur Pharmaceuticals, Inc. This filing also details how outstanding Denali ordinary shares, warrants and units converted into securities of the domesticated entity.
Form 8-K filings dated December 3, 2025 provide additional context on trading status. They state that the registrant’s securities were suspended from trading on The Nasdaq Capital Market and then began trading on the OTCQB marketplace under the symbols DNQAF, DNQWF and DNQUF. In connection with the domestication and Business Combination, the securities later began trading on the OTCQB marketplace under the symbols SMNR and SMNRW.
Registration statements on Form S-1 and Form S-1/A for Semnur Pharmaceuticals, Inc. further describe the registration of common stock and warrants, including shares issuable upon exercise of private placement warrants and public warrants originally sold in the initial public offering of Denali Capital Acquisition Corp. These documents identify Semnur Pharmaceuticals, Inc. as a non-accelerated filer, smaller reporting company and emerging growth company, and they outline how various categories of selling stockholders may offer and sell shares.
On this filings page, users can follow the sequence of 8-K reports and S-1/S-1A registration statements to understand the corporate restructuring, symbol changes from DNQAF to SMNR and SMNRW, and the treatment of warrants and other equity-linked securities as disclosed to the SEC.
Scilex Holding Co. and related reporting persons disclosed multiple dispositions of Semnur Pharmaceuticals, Inc. (SMNR) common stock executed under a Securities Purchase Agreement. The filing reports dispositions on 09/23/2025: a sale of 11,945,151 shares at a reported price of $16, an additional sale of 554,849 shares at $16, and indirect ownership reported of 6,250,000 shares by Scilex Bio, Inc. The filing shows an aggregate indirect beneficial ownership figure of 181,804,849 shares following one reported transaction. The purchase price for the transactions was stated to have been paid in Bitcoin based on the Coinbase spot rate at 8:00 p.m. New York time on the trading day before closing.
Reporting person: Shah Jaisim, listed at Semnur Pharmaceuticals, Inc. address in Palo Alto, CA, filed an Initial Statement of Beneficial Ownership related to Denali Capital Acquisition Corp. (ticker shown in filing: SMNR; metadata symbol: DNQWF) for an event dated 09/22/2025.
The filing reports a stock option exercisable under the Semnur Pharmaceuticals, Inc. 2024 Stock Option Plan that was issued with an exercise price of $1.27 and underlying 21,875,000 shares of the Issuer's common stock. The option vests monthly (1/48th per month) and generally became exercisable following shareholder approval tied to a Form S-4, but exercisability and other rights are suspended until payment in full of obligations under a Senior Secured Promissory Note dated 09/21/2023.
Stephen Ma, Chief Financial Officer, Senior Vice President and Secretary of Semnur Pharmaceuticals, filed an initial Form 3 reporting a direct stock option to buy 2,500,000 shares of Denali Capital Acquisition Corp. (ticker shown as SMNR in the filing). The option has a $1.27 exercise price and a term expiring 08/30/2034. The option vests monthly (1/48th per month) and became exercisable in connection with the completed business combination and option exchange approved by shareholders, but exercisability and attendant rights are suspended while a Senior Secured Promissory Note issued by Scilex Holding Company to Oramed Pharmaceuticals remains unpaid. The filing identifies the reporting person’s officer role and includes a signed power of attorney.
Wu Yue (Alexander) is reported as a director of Denali Capital Acquisition Corp. (ticker: SMNR). The Form 3 states the reporting person does not beneficially own any securities of the issuer and references a Power of Attorney (Exhibit 24). The statement lists the event date for the ownership report as 09/22/2025 and was signed by an attorney-in-fact on the reporting person's behalf.
Form 3 filed for Denali Capital Acquisition Corp. (SMNR) by Followwill Dorman lists the reporting relationship as a director and confirms no securities are beneficially owned as of the event date 09/22/2025. The filing is signed by an attorney-in-fact on 09/23/2025 and includes an Exhibit 24 power of attorney. This is an initial ownership statement reporting zero direct or indirect holdings.
Denali Capital Acquisition Corp. (SMNR) Form 3 reports initial beneficial ownership by Scilex-related entities following a business combination that closed under an amended merger agreement. Scilex, Inc. indirectly holds 193,750,000 shares of Denali Common Stock, Scilex Bio, Inc. holds 6,250,000 shares, and Scilex Holding Company directly holds 1,054,849 shares. The largest block reflects an exchange of Old Semnur shares into Denali Common Stock at an exchange ratio of 1.25 to 1. The filing documents share origins: exchanges from Series A Preferred, a pre-combination purchase, and conversion of a promissory note.
Ji Henry, Executive Chairperson and Director of Denali Capital Acquisition Corp. (Issuer listed as SMNR), filed an initial Form 3 disclosing a large stock option position tied to the company's business combination and subsequent corporate events. The filing shows a stock option exercisable through 08/30/2034 covering 21,875,000 shares of common stock at an exercise price of $1.27 per share. The option vests monthly in 1/48th installments and became exercisable following shareholder approval of an option exchange on 09/03/2025, but exercisability and related rights are suspended until a Senior Secured Promissory Note between Scilex Holding Company and Oramed Pharmaceuticals, Inc. is paid in full. The option reflects an exchange ratio of 1.25 applied when Old Semnur merged into the Issuer.